Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04142619
Title Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Cellectis S.A.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
UCSF Medical Center- Helen Diller Family Comprehensive Cancer Center San Francisco California 94115 United States Details
Sarah Cannon Research Institute - Colorado Blood Cancer Institute Denver Colorado 80218 United States Details
Winship Cancer Institute Emory University Atlanta Georgia 30322 United States Details
Mayo Clinical Cancer Center (MCCC) Rochester Minnesota 55905 United States Details
Hackensack Meridian Health Hackensack New Jersey 07601 United States Details
Sarah Cannon Research Institute - Tennessee Oncology Nashville Tennessee 37203-1625 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
Sarah Cannon Research Institute - Methodist Healthcare San Antonio Texas 78229-6306 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field